The Drug-Induced Respiratory Disease Website and App

Immune checkpoint inhibitors (ICI) - ICI combinatorial Rx

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XX.g

Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

Publications

Zhu J, He Z, Liang D, Yu X, Qiu K, Wu J

Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study.

Thorax 2022 Mar 11;; — 2022 Mar 11

Roussel L, Brindel A, Pouget C, Treffel G, Billon Y, Vaillant P, Tiotiu A

Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician.

Archivos de bronconeumologia 2021 Jun 04;; — 2021 Jun 04

Murakami S, Usui R, Nakahara Y, Kondo T, Kato T, Saito H

Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab Therapy.

Internal medicine (Tokyo, Japan) 2020 Dec 29;; — 2020 Dec 29

Elkington PT, Bateman AC, Thomas GJ, Ottensmeier CH

Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.

American journal of respiratory and critical care medicine 2018 Dec 01;198;1451-1453 — 2018 Dec 01 — 1451-1453

Jensen KH, Persson G, Bondgaard AL, Pøhl M

Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.

Acta oncologica (Stockholm, Sweden) 2018 08;57;1127-1128 — 2018 08 — 1127-1128

Picchi H, Mateus C, Chouaid C, Besse B, Marabelle A, Michot JM, Champiat S, Voisin AL, Lambotte O

Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2018 Mar;24;216-218 — 2018 Mar — 216-218

Reungwetwattana T, Adjei AA

Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 12;11;2048-2050 — 2016 12 — 2048-2050

Fujita K, Terashima T, Mio T

Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 12;11;2238-2240 — 2016 12 — 2238-2240